trending Market Intelligence /marketintelligence/en/news-insights/trending/BC6orM0UF9IZjXqQxZXcxw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca sells Seroquel's Europe, Russia rights to Cheplapharm

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AstraZeneca sells Seroquel's Europe, Russia rights to Cheplapharm

AstraZeneca PLC completed the sale of rights to its antipsychotic drug Seroquel and its extended-release version in Europe and Russia to privately held Cheplapharm Arzneimittel GmbH for $178 million up front.

Under the agreement, the Cambridge, U.K.-based pharmaceutical giant may also receive future sales-based payments of up to $61 million.

AstraZeneca said the funds will be used for general corporate purposes.

The company is also in the process of selling rights to Seroquel in the U.S. and Canada to Germany's Cheplapharm.

AstraZeneca has already sold the rights to the medicines to Chinese drugmaker Luye Pharma Group Ltd. in 2018 covering the U.K., China and 51 other countries, including Brazil, Australia and Mexico, under a $546 million deal.